vimarsana.com

Page 16 - பிரிட்டன் கூட்டு குழு ஆன் தடுப்பூசி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EU Regulator: AstraZeneca Vaccine Effective; Blood Clots May Be A Rare Side Effect

: : The European Union s drug regulator on Wednesday announced its findings into the possible connection between AstraZeneca s COVID-19 vaccine and rare blood clots. Updated April 7, 2021 at 11:52 AM ET The European Union s drug regulator said Wednesday that the benefits of AstraZeneca s COVID-19 vaccine outweigh its risks, but that rare blood clotting events should be listed as a possible side effect. The European Medicines Agency s assessment comes after a panel of experts reviewed reports of unusual blood clots occurring in some vaccine recipients. Officials stressed these events are rare and said that while they appear to be more common in women under the age of 60, there is not enough available evidence to confirm specific risk factors such as age, gender or previous medical history.

Don t give Oxford/AstraZeneca vaccine to under-30s: U K

Updated: Share Article AAA A vial of the AstraZeneca COVID-19 vaccine is seen in this file photo.   | Photo Credit: Reuters Britain should not giveOxford/AstraZeneca s COVID-19 vaccine to under 30s wherepossible, Britain s Joint Committee on Vaccination and Immunisation (JCVI) said on Wednesday, due to a very rare side-effect of blood clots in the brain. Wei Shen Lim, COVID-19 Chair for JCVI, said that based on the available data and evidence, the committee has advised that it is preferable for adults aged under 30 with no underlying conditions to be offered an alternative to the AstraZeneca vaccine where available. He said that for younger people, where the risks of hospitalisation were much lower, the risk/benefit calculation of the Oxford/AstraZeneca shot meant others vaccines were preferable.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.